Related Experiment Video
Updated: May 7, 2026
Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
Published on: November 8, 2016
Theranostic immunoliposomes for osteoarthritis
Hongsik Cho1, John M Stuart2, Richard Magid3
1University of Tennessee Health Science Center, Memphis, TN, USA; Campbell Clinnic, Memphis, TN, USA; Veterans Affairs Medical Center, Memphis, TN, USA.
Abstract:
Although there have been substantial advancements in the treatment of inflammatory arthritis, treatments for osteoarthritis (OA) have lagged and currently are primarily palliative until joints become totally dysfunctional and prosthetic replacement is needed. One obstacle for developing a preventive therapy for OA is the lack of good tools for efficiently diagnosing the disease and monitoring its progression during the early stages when the effect of therapeutic drugs or biologics is most likely to be effective. We have developed near infrared immunoliposomes conjugated with type II collagen antibody for diagnosis and treatment of early OA. These immunoliposomes bind to damaged but not normal cartilage. Utilizing these reagents, we can quantitate exposure of type II collagen during cartilage degradation in individual joints in vivo in a guinea pig. Immunoliposomes could be used to determine the effectiveness of therapeutic interventions in small animals as well as vehicles for localized drug delivery to OA chondrocytes.
From The Clinical Editor:
This team of authors have developed near infrared immunoliposomes conjugated with type II collagen antibody for diagnosis and treatment of early OA, with promising results demonstrated in a guinea pig model.
Insights
New near-infrared immunoliposomes target damaged cartilage for early osteoarthritis (OA) diagnosis and treatment. This innovative tool aids in monitoring disease progression and evaluating therapeutic effectiveness in preclinical models.
Area of Science:
- Biomedical Engineering
- Immunology
- Osteoarthritis Research
Background:
- Current osteoarthritis (OA) treatments are largely palliative, necessitating joint replacement.
- Early diagnosis and monitoring are crucial for effective OA therapy, but current tools are limited.
- Developing preventive strategies for OA is hindered by a lack of efficient diagnostic and progression monitoring methods.
Purpose of the Study:
- To develop novel near-infrared (NIR) immunoliposomes for early diagnosis and treatment of osteoarthritis (OA).
- To create a tool for quantifying type II collagen exposure during cartilage degradation in vivo.
- To assess the potential of these immunoliposomes as diagnostic agents and drug delivery vehicles for OA.
Main Methods:
- Conjugation of near-infrared fluorescent dyes to liposomes.
- Antibody targeting of type II collagen on damaged cartilage.
- In vivo imaging and quantification of cartilage degradation in a guinea pig model.
- Evaluation of immunoliposomes for localized drug delivery.
Main Results:
- Developed NIR immunoliposomes conjugated with type II collagen antibody.
- Demonstrated specific binding of immunoliposomes to damaged cartilage, not normal cartilage.
- Successfully quantified type II collagen exposure in vivo in a guinea pig model.
- Showcased potential for monitoring therapeutic intervention effectiveness and localized drug delivery.
Conclusions:
- NIR immunoliposomes offer a promising tool for early OA diagnosis and monitoring.
- These immunoliposomes can quantify cartilage degradation by measuring type II collagen exposure.
- The developed technology serves as a potential vehicle for targeted drug delivery to OA chondrocytes.
- This approach could significantly advance the development of preventive therapies for osteoarthritis.
